{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:19:47Z","timestamp":1788927587290,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Shanghai Health Commission","award":["202340160"],"award-info":[{"award-number":["202340160"]}]},{"name":"Science and technology development project of Shanghai University of Traditional Chinese Medicine","award":["24KFL065"],"award-info":[{"award-number":["24KFL065"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274338"],"award-info":[{"award-number":["82274338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04079-6","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T17:50:13Z","timestamp":1760464213000},"page":"1178-1197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-773X","authenticated-orcid":false,"given":"Minghe","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"1","key":"4079_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"4079_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.9","author":"C Gridelli","year":"2015","unstructured":"Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015. https:\/\/doi.org\/10.1038\/nrdp.2015.9.","journal-title":"Nat Rev Dis Primers"},{"key":"4079_CR3","doi-asserted-by":"publisher","DOI":"10.3816\/clc.2002.s.001","author":"CP Belani","year":"2002","unstructured":"Belani CP. Chemotherapy regimens in advanced non-small-cell lung cancer: recent randomized trials. Clin Lung Cancer. 2002. https:\/\/doi.org\/10.3816\/clc.2002.s.001.","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"4079_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/sj.cgt.7701120","volume":"15","author":"S Shamimi-Noori","year":"2008","unstructured":"Shamimi-Noori S, Yeow WS, Ziauddin MF, et al. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther. 2008;15(6):356\u201370. https:\/\/doi.org\/10.1038\/sj.cgt.7701120.","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"4079_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.bbrc.2016.03.053","volume":"473","author":"M Matsumoto","year":"2016","unstructured":"Matsumoto M, Nakajima W, Seike M, Gemma A, Tanaka N. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on bax- and bak-induction pathway and synergistically activated by bh3-mimetic abt-263 in p53 wild-type and mutant cells. Biochem Biophys Res Commun. 2016;473(2):490\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2016.03.053.","journal-title":"Biochem Biophys Res Commun"},{"key":"4079_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00092","author":"CY Sun","year":"2018","unstructured":"Sun CY, Zhu Y, Li XF, et al. Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell lung cancer via erk\/p53 and c-met\/akt signaling pathways. Front Pharmacol. 2018. https:\/\/doi.org\/10.3389\/fphar.2018.00092.","journal-title":"Front Pharmacol"},{"issue":"10","key":"4079_CR7","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00432-011-1021-1","volume":"137","author":"E Ulukaya","year":"2011","unstructured":"Ulukaya E, Ari F, Dimas K, et al. Cell death-inducing effect of novel palladium(ii) and platinum(ii) complexes on non-small cell lung cancer cells in vitro. J Cancer Res Clin Oncol. 2011;137(10):1425\u201334. https:\/\/doi.org\/10.1007\/s00432-011-1021-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"4079_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(09)70364-X.","journal-title":"Lancet Oncol"},{"issue":"21","key":"4079_CR9","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543\u201351. https:\/\/doi.org\/10.1200\/JCO.2007.15.0375.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4079_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1056\/NEJMoa060570","volume":"355","author":"KA Olaussen","year":"2006","unstructured":"Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983\u201391. https:\/\/doi.org\/10.1056\/NEJMoa060570.","journal-title":"N Engl J Med"},{"key":"4079_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.598817","volume":"10","author":"N Gao","year":"2020","unstructured":"Gao N, Li Y, Li J, et al. Long non-coding rnas: the regulatory mechanisms, research strategies, and future directions in cancers. Front Oncol. 2020;10:598817. https:\/\/doi.org\/10.3389\/fonc.2020.598817.","journal-title":"Front Oncol"},{"issue":"2","key":"4079_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96\u2013118. https:\/\/doi.org\/10.1038\/s41580-020-00315-9.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"28","key":"4079_CR13","doi-asserted-by":"publisher","first-page":"44719","DOI":"10.18632\/oncotarget.8089","volume":"7","author":"M Meryet-Figui\u00e8re","year":"2016","unstructured":"Meryet-Figui\u00e8re M, Lambert B, Gauduchon P, et al. An overview of long non-coding RNAs in ovarian cancers. Oncotarget. 2016;7(28):44719\u201334. https:\/\/doi.org\/10.18632\/oncotarget.8089.","journal-title":"Oncotarget"},{"issue":"7","key":"4079_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3179","volume":"22","author":"W Ai","year":"2020","unstructured":"Ai W, Li F, Yu HH, Liang ZH, Zhao HP. Up-regulation of long noncoding rna linc00858 is associated with poor prognosis in gastric cancer. J Gene Med. 2020;22(7):e3179. https:\/\/doi.org\/10.1002\/jgm.3179.","journal-title":"J Gene Med"},{"key":"4079_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.785839","volume":"12","author":"W Jiang","year":"2021","unstructured":"Jiang W, Song Y, Zhong Z, Gao J, Meng X. Ferroptosis-related long non-coding RNA signature contributes to the prediction of prognosis outcomes in head and neck squamous cell carcinomas. Front Genet. 2021;12:785839. https:\/\/doi.org\/10.3389\/fgene.2021.785839.","journal-title":"Front Genet"},{"issue":"27","key":"4079_CR16","doi-asserted-by":"publisher","first-page":"44195","DOI":"10.18632\/oncotarget.17409","volume":"8","author":"M Shi","year":"2017","unstructured":"Shi M, Zhang XY, Yu H, et al. Ddx11-as1 as potential therapy targets for human hepatocellular carcinoma. Oncotarget. 2017;8(27):44195\u2013202. https:\/\/doi.org\/10.18632\/oncotarget.17409.","journal-title":"Oncotarget"},{"key":"4079_CR17","doi-asserted-by":"publisher","first-page":"154654","DOI":"10.1016\/j.prp.2023.154654","volume":"248","author":"H Akhgari","year":"2023","unstructured":"Akhgari H, Shokri N, Dehghanzadeh P, Tayefeh-Gholami S, Rajabi A, Safaralizadeh R. Expression pattern of pcat1, pcat2, and pcat5 lncrnas and their value as diagnostic biomarkers in patients with gastric cancer. Pathol Res Pract. 2023;248:154654. https:\/\/doi.org\/10.1016\/j.prp.2023.154654.","journal-title":"Pathol. Res. Pract."},{"issue":"2","key":"4079_CR18","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.18632\/oncotarget.6450","volume":"7","author":"S Gao","year":"2016","unstructured":"Gao S, Wang P, Hua Y, et al. Ror functions as a cerna to regulate nanog expression by sponging mir-145 and predicts poor prognosis in pancreatic cancer. Oncotarget. 2016;7(2):1608\u201318. https:\/\/doi.org\/10.18632\/oncotarget.6450.","journal-title":"Oncotarget"},{"issue":"2","key":"4079_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cell.2018.03.059","volume":"173","author":"A Blum","year":"2018","unstructured":"Blum A, Wang P, Zenklusen JC. Snapshot: tcga-analyzed tumors. Cell. 2018;173(2):530. https:\/\/doi.org\/10.1016\/j.cell.2018.03.059.","journal-title":"Cell"},{"key":"4079_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-1-4939-3578-9_6","volume":"1418","author":"Z Wang","year":"2016","unstructured":"Wang Z, Jensen MA, Zenklusen JC. A practical guide to the cancer genome atlas (tcga). Methods Mol Biol. 2016;1418:111\u201341. https:\/\/doi.org\/10.1007\/978-1-4939-3578-9_6.","journal-title":"Methods Mol Biol"},{"key":"4079_CR21","doi-asserted-by":"publisher","first-page":"D991","DOI":"10.1093\/nar\/gks1193","volume":"41","author":"T Barrett","year":"2013","unstructured":"Barrett T, Wilhite SE, Ledoux P, et al. Ncbi geo: archive for functional genomics data sets\u2013update. Nucleic Acids Res. 2013;41:D991\u20135. https:\/\/doi.org\/10.1093\/nar\/gks1193.","journal-title":"Nucleic Acids Res."},{"key":"4079_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-1-4939-3578-9_5","volume":"1418","author":"E Clough","year":"2016","unstructured":"Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol. 2016;1418:93\u2013110. https:\/\/doi.org\/10.1007\/978-1-4939-3578-9_5.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"4079_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cell.2018.03.042","volume":"173","author":"C Hutter","year":"2018","unstructured":"Hutter C, Zenklusen JC. The cancer genome atlas: creating lasting value beyond its data. Cell. 2018;173(2):283\u20135. https:\/\/doi.org\/10.1016\/j.cell.2018.03.042.","journal-title":"Cell"},{"issue":"2","key":"4079_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","volume":"16","author":"JC Yang","year":"2015","unstructured":"Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(14)71173-8.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4079_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/JTO.0b013e3181753b38","volume":"3","author":"Y Naito","year":"2008","unstructured":"Naito Y, Kubota K, Nihei K, et al. Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage iii non-small cell lung cancer. J Thorac Oncol. 2008;3(6):617\u201322. https:\/\/doi.org\/10.1097\/JTO.0b013e3181753b38.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"4079_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113295","volume":"42","author":"AM Zavitsanou","year":"2023","unstructured":"Zavitsanou AM, Pillai R, Hao Y, et al. Keap1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance. Cell Rep. 2023;42(11):113295. https:\/\/doi.org\/10.1016\/j.celrep.2023.113295.","journal-title":"Cell Rep"},{"key":"4079_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008811","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhou Y, Ren R, Chen Y, Lei J, Li Y. Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-008811.","journal-title":"J Immunother Cancer"},{"key":"4079_CR28","doi-asserted-by":"publisher","first-page":"108992","DOI":"10.1016\/j.clim.2022.108992","volume":"238","author":"X Cheng","year":"2022","unstructured":"Cheng X, Wang J, Qiu C, et al. Feasibility of inkt cell and pd-1+cd8+ t cell-based immunotherapy in patients with lung adenocarcinoma: preliminary results of a phase i\/ii clinical trial. Clin Immunol. 2022;238:108992. https:\/\/doi.org\/10.1016\/j.clim.2022.108992.","journal-title":"Clin Immunol."},{"issue":"7","key":"4079_CR29","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, et al. Stk11\/lkb1 mutations and PD-1 inhibitor resistance in kras-mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0099.","journal-title":"Cancer Discov"},{"key":"4079_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01323-7","volume":"20","author":"ZG Sun","year":"2020","unstructured":"Sun ZG, Pan F, Shao JB, Yan QQ, Lu L, Zhang N. Kinesin superfamily protein 21b acts as an oncogene in non-small cell lung cancer. Cancer Cell Int. 2020;20:233. https:\/\/doi.org\/10.1186\/s12935-020-01323-7.","journal-title":"Cancer Cell Int"},{"key":"4079_CR31","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.2147\/CMAR.S236565","volume":"12","author":"Y Sun","year":"2020","unstructured":"Sun Y, Liu T, Xian L, Liu W, Liu J, Zhou H. B3gnt3, a direct target of mir-149-5p, promotes lung cancer development and indicates poor prognosis of lung cancer. Cancer Manag Res. 2020;12:2381\u201391. https:\/\/doi.org\/10.2147\/CMAR.S236565.","journal-title":"Cancer Manag Res"},{"issue":"16","key":"4079_CR32","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.7150\/jca.31832","volume":"10","author":"M Xiao","year":"2019","unstructured":"Xiao M, Cui S, Zhang L, et al. Ac138128.1 an intronic lncrna originating from ercc1 implies a potential application in lung cancer treatment. J Cancer. 2019;10(16):3608\u201317. https:\/\/doi.org\/10.7150\/jca.31832.","journal-title":"J Cancer"},{"issue":"1","key":"4079_CR33","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ymthe.2021.06.006","volume":"30","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Guo H, Tong T, et al. LncRNA lnc-pop1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous cell carcinoma through interaction with MCM5. Mol Ther. 2022;30(1):448\u201367. https:\/\/doi.org\/10.1016\/j.ymthe.2021.06.006.","journal-title":"Mol Ther"},{"issue":"5","key":"4079_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12474","volume":"51","author":"S Gong","year":"2018","unstructured":"Gong S, Chen Y, Meng F, et al. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP\/PKA\/CREB-FTMT signalling axis. Cell Prolif. 2018;51(5):e12474. https:\/\/doi.org\/10.1111\/cpr.12474.","journal-title":"Cell Prolif"},{"issue":"5","key":"4079_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26853","volume":"10","author":"Y Deng","year":"2024","unstructured":"Deng Y, Ding H, Zhang Y, et al. Tp53 mitigates cisplatin resistance in non-small cell lung cancer by mediating the effects of resistant cell-derived exosome mir-424-5p. Heliyon. 2024;10(5):e26853. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26853.","journal-title":"Heliyon"},{"issue":"1","key":"4079_CR36","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1038\/s41467-024-47080-3","volume":"15","author":"YY Bi","year":"2024","unstructured":"Bi YY, Chen Q, Yang MY, Xing L, Jiang HL. Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer. Nat Commun. 2024;15(1):2759. https:\/\/doi.org\/10.1038\/s41467-024-47080-3.","journal-title":"Nat Commun"},{"issue":"1","key":"4079_CR37","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1038\/s41598-023-29684-9","volume":"13","author":"L Li","year":"2023","unstructured":"Li L, Cai Q, Wu Z, et al. Bioinformatics construction and experimental validation of a cuproptosis-related lncRNA prognostic model in lung adenocarcinoma for immunotherapy response prediction. Sci Rep. 2023;13(1):2455. https:\/\/doi.org\/10.1038\/s41598-023-29684-9.","journal-title":"Sci Rep"},{"key":"4079_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12112891","author":"Z Zeng","year":"2022","unstructured":"Zeng Z, Liang Y, Shi J, et al. Identification and application of a novel immune-related lncrna signature on the prognosis and immunotherapy for lung adenocarcinoma. Diagnostics. 2022. https:\/\/doi.org\/10.3390\/diagnostics12112891.","journal-title":"Diagnostics"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04079-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04079-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04079-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:13:03Z","timestamp":1774415583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04079-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4079"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04079-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors declare their consent to the publication of the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}